Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc. reported a net loss of $412.8 million for fiscal year 2025, driven by significant operating expenses of $526.2 million that far exceeded total product revenue of $54.0 million. The company generated a loss from operations of $472.1 million, though this was partially offset by interest income of $56.4 million and other income of $2.0 million. Cash flow from operations was negative $373.0 million, but the company maintained strong liquidity with total assets of $1.30 billion, including $89.1 million in cash and cash equivalents and $1.08 billion in marketable securities. The balance sheet shows minimal liabilities of $104.1 million against stockholders' equity of $1.19 billion, with an accumulated deficit of $561.7 million. No prior year comparative figures are provided in the source data for year-over-year analysis.

Key Takeaways